


1645



| TRANSMITTAL LETTER | | | Case No. 9793/93 |
|---|---------------------------------|------------------------------|------------------------|
| Serial No. 10/057,762 | Filing Date January 25, 2002 | Examiner Not yet assigned | Group Art Unit 1645 |
| Inventor(s) Min Li et al. | | | |
| Title of Invention WATER-SOLUBLE DERIVATIVES OF LIPOPHILIC DRUGS | | | |

RECEIVED
JAN 22 2004
TECH CENTER 1600/2900

TO THE COMMISSIONER FOR PATENTS


Transmitted herewith is a Second Supplemental Information Disclosure Statement (in duplicate); From PTO-1449;
4 Cited References (C1-C4); Return Postcard.

- ☐ Small entity status of this application under 37 CFR § 1.27 has been established by verified statement previously submitted.
- ☐ Applicant claims small entity status. See 37 CFR 1.27.
- ☐ Petition for a _____ month extension of time.
- ☒ No additional fee is required.
- ☐ The fee has been calculated as shown below:

| | | | | | Small Entity | | or | Other Than Small Entity | |
|---|----------------------------------|-------|---------------------------------|---------------|-----------------|-----------|----|-------------------------|-----------|
| | Claims Remaining After Amendment | | Highest No. Previously Paid For | Present Extra | Rate | Add'l Fee | | Rate | Add'l Fee |
| Total | | Minus | | | x \$9 = | | | x \$18 = | |
| Indep. | | Minus | | | x 43 = | | | x \$86 = | |
| First Presentation of Multiple Dep. Claim | | | | | + \$145 = | | | + \$290 = | |
| | | | | | Total add'l fee | \$ | | Total add'l fee | \$ |


- ☐ Please charge Deposit Account No. 23-1925 (BRINKS HOFER GILSON & LIONE) in the amount of \$ _____. A duplicate copy of this sheet is enclosed.
- ☐ A check in the amount of \$ _____ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 CFR § 1.16 and any patent application processing fees under 37 CFR § 1.17 associated with this communication or credit any overpayment to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.
- ☒ I hereby petition under 37 CFR § 1.136(a) for any extension of time required to ensure that this paper is timely filed. Please charge any associated fees which have not otherwise been paid to Deposit Account No. 23-1925. A duplicate copy of this sheet is enclosed.

Respectfully submitted,


Jonathan P. Taylor, Ph.D.
Registration No. 48,338
Agent for Applicant
Customer No. 00757 - Brinks Hofer Gilson Lione

BRINKS HOFER GILSON & LIONE
P.O. BOX 10395
CHICAGO, ILLINOIS 60610
(312) 321-4200

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on January 14, 2004

Date: 1/14/04 Signature: 



CERTIFICATE OF MAILING



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope, with sufficient postage, addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

RECEIVED
JAN 22 2004
TECH CENTER 1600/2900

January 14, 2004

Date of Deposit

Jonathan P. Taylor, Ph.D., Reg. No. 48,338

Name of Applicant, Assignee or
Registered Representative


Signature

1/14/04

Date of Signature

Our Case No.: 9793/93

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Min-Li et al.

Serial No.: 10/057,762

Filing Date: January 25, 2002

For: WATER-SOLUBLE DERIVATIVES
OF LIPOPHILIC DRUGS

Examiner: Not yet assigned

Group Art Unit No.: 1645

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Second Supplemental Information Disclosure Statement be entered and the documents listed below and on the attached Form PTO-1449 be considered by the Examiner and made of record. Copies of the listed documents required by 37 C.F.R. § 1.98(a)(2) are enclosed for the convenience of the Examiner.

The references now cited are the following:

U.S. Patent References

| DOCUMENT NUMBER <small>Number-Kind Code (if known)</small> | DATE | NAME |
|--|---------|---------------|
| 5,847,128 | 12/1998 | Martin et al. |

Foreign Art References

| DOCUMENT NUMBER <small>Number-Kind Code (if known)</small> | DATE | COUNTRY |
|--|---------|---------|
| WO 01/98289 A1 | 12/2001 | PCT |

Other Art References

| OTHER ART – NON PATENT LITERATURE DOCUMENTS <small>(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.</small> |
|--|
| Yoshimura, Hidetoshi et al., "Synthesis and Pharmacological Activity of a Phosphate Ester of Δ^8 -Tetrahydrocannabinol", <i>Journal of Medicinal Chemistry</i> , (1978), Vol. 21, No. 10, pp. 1079-1081. |
| Zoller, Otmar et al., "High-performance liquid chromatographic determination of Δ^9 -tetrahydrocannabinol and the corresponding acid in hemp containing foods with special regard to the fluorescence properties of Δ^9 -tetrahydrocannabinol", <i>Journal of Chromatography A</i> , (2000), 872, pp. 101-110. |

In accordance with 37 C.F.R. § 1.97(g),(h), this Second Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).


This Second Supplemental Information Disclosure Statement is being filed prior to the receipt of the first Official Action reflecting an examination on the merits and hence is believed to be timely filed in accordance with 37 C.F.R. § 1.97(b). No fees are believed to be due in connection with filing of this Second Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these material, the Commissioner is

hereby authorized to deduct said fees from Brinks Hofer Gilson & Lione Deposit
Account No. 23-1925. A duplicate copy of this document is enclosed.

Applicant(s) respectfully request that the listed documents be made of record in
the present case.

Respectfully submitted,

1/14/04



Jonathan P. Taylor, Ph.D.
Registration No. 48,338
Agent for Applicant(s)

BRINKS HOFER GILSON & LIONE
P.O. Box 10395
Chicago, IL 60610
(312) 321-4200

